Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60318 |
Name | acute promyelocytic leukemia |
Definition | An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia acute promyelocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FLT3 D835Y | Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin | acute promyelocytic leukemia | predicted - sensitive | detail... |
FLT3 D835Y | Tretinoin | acute promyelocytic leukemia | predicted - resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01409161 | Phase II | Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | Recruiting | USA | 0 |
NCT01869803 | Phase I | Gemtuzumab ozogamicin | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | Approved for marketing | USA | 0 |
NCT02339740 | Phase III | Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
NCT02688140 | Phase III | Arsenic trioxide + Idarubicin + Tretinoin Mercaptopurine + Methotrexate + Tretinoin Cytarabine + Idarubicin + Tretinoin Mitoxantrone + Tretinoin Idarubicin + Tretinoin | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) | Active, not recruiting | NLD | ITA | FRA | ESP | DEU | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT04793919 | Phase II | Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin Arsenic trioxide + Tretinoin | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | Recruiting | SWE | NLD | ITA | ISR | IRL | FRA | ESP | DNK | DEU | CZE | BEL | 1 |
NCT04996030 | Phase I | Arsenic trioxide + SY-2101 SY-2101 Arsenic trioxide | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Suspended | USA | 0 |